Literature DB >> 24484337

Rationale for anticoagulant therapy of pulmonary fibrosis.

Galina S Bogatkevich1, Paul J Nietert, Richard M Silver, Kristin B Highland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24484337      PMCID： PMC3977727          DOI： 10.1164/rccm.201305-0845LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  6 in total

1.  Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.

Authors:  H Yasui; E C Gabazza; S Tamaki; T Kobayashi; O Hataji; H Yuda; S Shimizu; K Suzuki; Y Adachi; O Taguchi
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

2.  Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Paul J Nietert; Tanjina Akter; Joanne van Ryn; Richard M Silver
Journal:  Arthritis Rheum       Date:  2011-05

Review 3.  Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

Authors:  R C Chambers
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

4.  Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.

Authors:  T Ohba; J K McDonald; R M Silver; C Strange; E C LeRoy; A Ludwicka
Journal:  Am J Respir Cell Mol Biol       Date:  1994-04       Impact factor: 6.914

5.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Authors:  Imre Noth; Kevin J Anstrom; Sara Bristol Calvert; Joao de Andrade; Kevin R Flaherty; Craig Glazer; Robert J Kaner; Mitchell A Olman
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

6.  Role of thrombin in pulmonary fibrosis.

Authors:  N A Hernández-Rodríguez; A D Cambrey; N K Harrison; R C Chambers; A J Gray; A M Southcott; R M duBois; C M Black; M F Scully; R J McAnulty
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321
  6 in total
  2 in total

1.  Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.

Authors:  Barry S Shea; Clemens K Probst; Patricia L Brazee; Nicholas J Rotile; Francesco Blasi; Paul H Weinreb; Katharine E Black; David E Sosnovik; Elizabeth M Van Cott; Shelia M Violette; Peter Caravan; Andrew M Tager
Journal:  JCI Insight       Date:  2017-05-04

2.  Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.

Authors:  R M Silver; D A Wilson; T Akter; I Atanelishvili; J T Huggins; K Kajdasz; K B Highland; P J Nietert; G S Bogatkevich
Journal:  ACR Open Rheumatol       Date:  2019-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.